4.6 Article

SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation

Journal

CARCINOGENESIS
Volume 42, Issue 2, Pages 180-189

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgaa131

Keywords

-

Categories

Funding

  1. AMED [JP20ck0106552]
  2. JSPS KAKENHI [JP18H02704]

Ask authors/readers for more resources

The study identified SAA1 as a potential therapeutic target from primary gastric CAFs, with its upregulation likely mediated by enhancer activation. Experimental results showed that overexpression of SAA1 can enhance the migration ability of gastric cancer cells, indicating its important role in gastric cancer growth.
Cancer-associated fibroblasts (CAFs) tend to have tumor-promoting capacity, and can provide therapeutic targets. Even without cancer cells, CAF phenotypes are stably maintained, and DNA methylation and H3K27me3 changes have been shown to be involved. Here, we searched for a potential therapeutic target in primary CAFs from gastric cancer and a mechanism for its dysregulation. Expression microarray using eight CAFs and seven non-CAFs (NCAFs) revealed that serum amyloid A1 (SAA1), which encodes an acute phase secreted protein, was second most upregulated in CAFs, following IGF2. Conditioned medium (CM) derived from SAA1-overexpressing NCAFs was shown to increase migration of gastric cancer cells compared with that from control NCAFs, and its tumor-promoting effect was comparable to that of CM from CAFs. In addition, increased migration of cancer cells by CM from CAFs was mostly canceled with CM from CAFs with SAA1 knockdown. Chromatin immunoprecipitation (ChIP)-quantitative PCR showed that CAFs had higher levels of H3K27ac, an active enhancer mark, in the promoter and the two far upstream regions of SAA1 than NCAFs. Also, BET bromodomain inhibitors, JQ1 and mivebresib, decreased SAA1 expression and tumor-promoting effects in CAFs, suggesting SAA1 upregulation by enhancer activation in CAFs. Our present data showed that SAA1 is a candidate therapeutic target from gastric CAFs and indicated that increased enhancer acetylation is important for its overexpression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Methylation silencing of ULK2 via epithelial-mesenchymal transition causes transformation to poorly differentiated gastric cancers

Iori Motoo, Sohachi Nanjo, Takayuki Ando, Satoshi Yamashita, Toshikazu Ushijima, Ichiro Yasuda

Summary: The study reveals that in diffuse-type gastric cancers, ULK2 is methylated and knockdown of ULK2 can induce autophagy, cell migration, and EMT. mRNA microarray analysis showed that knockdown of ULK2 altered the expressions of oncogenic genes associated with cell migration and EMT.

GASTRIC CANCER (2022)

Article Oncology

Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation

Chun-Dong Zhang, Hideyuki Takeshima, Shigeki Sekine, Satoshi Yamashita, Yu-Yu Liu, Naoko Hattori, Hiroyuki Abe, Hiroharu Yamashita, Masahide Fukuda, Yu Imamura, Tetsuo Ushiku, Hitoshi Katai, Hiroshi Makino, Masayuki Watanabe, Yasuyuki Seto, Toshikazu Ushijima

Summary: The study aimed to develop a marker for predicting the tissue origin of esophagogastric junction adenocarcinomas based on DNA methylation profiles, identifying two highly specific GAC markers. These markers successfully predicted the tissue origin of EGJ adenocarcinoma in FFPE samples.

GASTRIC CANCER (2022)

Review Multidisciplinary Sciences

Mapping genomic and epigenomic evolution in cancer ecosystems

Toshikazu Ushijima, Susan J. Clark, Patrick Tan

Summary: Cancer, driven by genomic and epigenomic derangements, requires multimodal data integration to understand the molecular evolution of malignant cell states across its lifecycle. Driver mutations and epigenetic alterations in normal-appearing tissues prompt a reassessment of cancer initiation, while studying clonal selection, epigenomic adaptation, and persister cells in metastasis and therapy resistance is an emerging field. The importance of tumor ecosystems in cancer development is being unveiled by advancing single-cell and spatial technologies.

SCIENCE (2021)

Article Gastroenterology & Hepatology

Autoimmune gastritis induces aberrant DNA methylation reflecting its carcinogenic potential

Chihiro Takeuchi, Junichi Sato, Satoshi Yamashita, Akiko Sasaki, Takemi Akahane, Rika Aoki, Mitsue Yamamichi, Yu-Yu Liu, Masayoshi Ito, Takahisa Furuta, Shigemi Nakajima, Yoshiki Sakaguchi, Yu Takahashi, Yosuke Tsuji, Keiko Niimi, Shuta Tomida, Mitsuhiro Fujishiro, Nobutake Yamamichi, Toshikazu Ushijima

Summary: Autoimmune gastritis induces aberrant DNA methylation in gastric mucosa, but to a lesser extent than H. pylori-associated gastritis. The patterns of methylation are also distinct between the two conditions.

JOURNAL OF GASTROENTEROLOGY (2022)

Article Oncology

DNA methylation marker to estimate ovarian cancer cell fraction

Takahiro Ebata, Satoshi Yamashita, Hideyuki Takeshima, Hiroshi Yoshida, Yoshiko Kawata, Nao Kino, Toshiharu Yasugi, Yasuhisa Terao, Kan Yonemori, Tomoyasu Kato, Toshikazu Ushijima

Summary: This study aimed to identify markers for evaluating ovarian cancer cell fraction. Using genome-wide DNA methylation data, SIM1 and ZNF154 were found to be highly correlated with pathological cancer cell fractions. Pyrosequencing primers were successfully designed for cost-effective analysis. In an independent validation cohort, ZNF154 methylation showed a significant correlation with the pathological cancer cell fraction.

MEDICAL ONCOLOGY (2022)

Article Oncology

ARID1A loss-of-function induces CpG island methylator phenotype

Harumi Yamada, Hideyuki Takeshima, Ryoji Fujiki, Satoshi Yamashita, Shigeki Sekine, Takayuki Ando, Naoko Hattori, Atsushi Okabe, Takaki Yoshikawa, Kazutaka Obama, Hitoshi Katai, Atsushi Kaneda, Toshikazu Ushijima

Summary: The CpG island methylator phenotype (CIMP) is associated with prognosis and drug sensitivity in multiple cancer types. This study demonstrates that mutations in the SWI/SNF chromatin remodeling complex, particularly ARID1A, are associated with CIMP induction in gastric cancer, as well as in uterine endometrial and colorectal cancers. The loss of ARID1A function causes aberrant DNA methylation and is likely a potential mechanism for CIMP induction.

CANCER LETTERS (2022)

Article Multidisciplinary Sciences

A quantification method of somatic mutations in normal tissues and their accumulation in pediatric patients with chemotherapy

Sho Uedaa, Satoshi Yamashita, Miho Nakajima, Tadashi Kumamoto, Chitose Ogawa, Yu-Yu Liu, Harumi Yamada, Emi Kubo, Naoko Hattori, Hideyuki Takeshima, Mika Wakabayashi, Naoko Iida, Yuichi Shiraishi, Masayuki Noguchi, Yukio Sato, Toshikazu Ushijima

Summary: This study developed a cost-effective pipeline called EcoSeq, which utilizes duplex sequencing to accurately count somatic mutations in single DNA molecules. The researchers used this method to analyze normal blood cells from pediatric sarcoma patients and found that the mutation frequency significantly increased in patients who received chemotherapy, with the increased frequency persisting even months after chemotherapy. This suggests that mutation accumulation poses a risk of secondary leukemia.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Oncology

DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer

Takahiro Ebata, Satoshi Yamashita, Hideyuki Takeshima, Hiroshi Yoshida, Yoshiko Kawata, Nao Kino, Toshiharu Yasugi, Yasuhisa Terao, Kan Yonemori, Tomoyasu Kato, Toshikazu Ushijima

Summary: A quantitative method was established to evaluate the DNA methylation level of the immediate upstream region of major BRCA1 transcriptional start sites (TSSs). The methylation of this region was found to be an independent favorable prognostic factor in high-grade serous ovarian cancer patients.

GYNECOLOGIC ONCOLOGY (2022)

Article Cell Biology

Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo

Takatsune Shimizu, Eiji Sugihara, Hideyuki Takeshima, Hiroyuki Nobusue, Rui Yamaguchi, Sayaka Yamaguchi-Iwai, Yumi Fukuchi, Toshikazu Ushijima, Akihiro Muto, Hideyuki Saya

Summary: Mutant p53 in osteosarcoma cells does not suppress the activity of wild-type p53. Targeting mutant p53 R270C (equivalent to human R273C) has limited therapeutic potential, as it does not prevent invasion and metastasis in cells.

CELLS (2022)

Article Hematology

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL

Yuki Kurahashi, Tatsuro Watanabe, Yuta Yamamoto, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Satoshi Yamashita, Naoko Hattori, Hideaki Nakamura, Atsushi Kawaguchi, Toshikazu Ushijima, Eisaburo Sueoka, Shinya Kimura

Summary: Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1). Epigenetic abnormalities, such as DNA methylation and trimethylation at histone H3Lys27 (H3K27me3), contribute to ATL development. Combination treatment with DNA demethylating agents and enhancer of zeste homolog 2 (EZH2) inhibitors showed synergistic anti-ATL effects by inducing gene expression reprogramming and restoring DUSP5, a key molecule that inactivates the ERK signaling pathway. This study suggests that dual targeting of aberrant DNA and histone methylation is a feasible therapeutic approach for ATL.

BLOOD ADVANCES (2023)

Article Oncology

HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity

Nobuaki Arai, Naoko Hattori, Satoshi Yamashita, Yu-Yu Liu, Takahiro Ebata, Chihiro Takeuchi, Hideyuki Takeshima, Satoshi Fujii, Haruhiko Kondo, Hirofumi Mukai, Toshikazu Ushijima

Summary: The aim of this study was to explore the methylation-silencing mechanism of the HSD17B4 gene in HER2-positive breast cancer. Knocking out the HSD17B4 gene led to suppressed cell proliferation, enhanced sensitivity to lapatinib, accumulation of VLCFA, decrease in polyunsaturated fatty acids, increased Akt phosphorylation, and upregulation of genes involved in oxidative phosphorylation and electron transport chain.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Meeting Abstract Oncology

Identification of enhancer methylation associated with resistance of ovarian cancer after neoadjuvant chemotherapy

Takahrio Ebata, Satoshi Yamashita, Hiroshi Yoshida, Tomoyasu Kato, Toshikazu Ushijima

CANCER SCIENCE (2021)

No Data Available